Business Context and Reporting Period
This Form 8-K Current Report was filed by Karyopharm Therapeutics Inc. on February 25, 2019. The filing primarily addresses Item 5.02 regarding the appointment of a new executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation details:
- Base Salary: $400,000 annually for the new Chief Financial Officer.
- Sign-on Bonus: $75,000 one-time payment.
- Annual Bonus Target: 40% of annualized base salary.
- Stock Option Grant: 150,000 shares with an exercise price of $5.06 per share.
Material Changes
The material change reported is the appointment of Michael Mason as Senior Vice President, Chief Financial Officer, and Treasurer, effective February 25, 2019. Additionally, Mr. Mason is designated to become the Company's principal financial officer and principal accounting officer effective March 2, 2019, replacing Cameron Peters who served in an interim capacity.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. Specific contingencies related to the new executive's employment include:
- Bonus Clawback: Mr. Mason must repay 100% of the sign-on bonus if terminated for Cause or resigns without Good Reason within one year, and 50% if within two years.
- Severance: Entitlement to up to six months of base salary upon termination without Cause or resignation for Good Reason, increasing to twelve months if such termination occurs within one year of a Change in Control.
- Stock Option Vesting: 25% vests on the first anniversary, with the remainder vesting monthly thereafter. Full acceleration occurs upon termination without Cause or resignation for Good Reason within one year of a Change in Control.
Investor Verification Checklist
- Verify the effective date of Michael Mason's appointment as CFO (February 25, 2019) and as principal financial/accounting officer (March 2, 2019).
- Confirm the terms of the 150,000 share stock option grant, specifically the $5.06 exercise price and vesting schedule.
- Review the attached Offer Letter (Exhibit 10.1) and Option Agreement (Exhibit 10.2) for full definitions of "Cause," "Good Reason," and "Change in Control."
- Note that this filing does not contain updated financial results; refer to the upcoming Form 10-K for the year ended December 31, 2018, for financial data.